The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Deferasirox Market Research Report 2024
Synopsis
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
The global Deferasirox market was valued at US$ 2729.8 million in 2023 and is anticipated to reach US$ 3728.5 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
This report aims to provide a comprehensive presentation of the global market for Deferasirox, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Deferasirox.
Report Scope
The Deferasirox market size, estimations, and forecasts are provided in terms of sales volume (M Tablets) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Deferasirox market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Deferasirox manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Cipla
Natco Pharma
Sun Pharma
Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Deferasirox manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Deferasirox in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
The global Deferasirox market was valued at US$ 2729.8 million in 2023 and is anticipated to reach US$ 3728.5 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
This report aims to provide a comprehensive presentation of the global market for Deferasirox, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Deferasirox.
Report Scope
The Deferasirox market size, estimations, and forecasts are provided in terms of sales volume (M Tablets) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Deferasirox market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Deferasirox manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Cipla
Natco Pharma
Sun Pharma
Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Deferasirox manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Deferasirox in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Deferasirox Market Overview
1.1 Product Overview and Scope of Deferasirox
1.2 Deferasirox Segment by Type
1.2.1 Global Deferasirox Market Value Comparison by Type (2024-2030)
1.2.2 500 mg/Tablet
1.2.3 250 mg/Tablet
1.2.4 125 mg/Tablet
1.2.5 Others
1.3 Deferasirox Segment by Application
1.3.1 Global Deferasirox Market Value by Application: (2024-2030)
1.3.2 Transfusional Iron Overload
1.3.3 NTDT Caused Iron Overload
1.4 Global Deferasirox Market Size Estimates and Forecasts
1.4.1 Global Deferasirox Revenue 2019-2030
1.4.2 Global Deferasirox Sales 2019-2030
1.4.3 Global Deferasirox Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Deferasirox Market Competition by Manufacturers
2.1 Global Deferasirox Sales Market Share by Manufacturers (2019-2024)
2.2 Global Deferasirox Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Deferasirox Average Price by Manufacturers (2019-2024)
2.4 Global Deferasirox Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Deferasirox, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Deferasirox, Product Type & Application
2.7 Deferasirox Market Competitive Situation and Trends
2.7.1 Deferasirox Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Deferasirox Players Market Share by Revenue
2.7.3 Global Deferasirox Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Deferasirox Retrospective Market Scenario by Region
3.1 Global Deferasirox Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Deferasirox Global Deferasirox Sales by Region: 2019-2030
3.2.1 Global Deferasirox Sales by Region: 2019-2024
3.2.2 Global Deferasirox Sales by Region: 2025-2030
3.3 Global Deferasirox Global Deferasirox Revenue by Region: 2019-2030
3.3.1 Global Deferasirox Revenue by Region: 2019-2024
3.3.2 Global Deferasirox Revenue by Region: 2025-2030
3.4 North America Deferasirox Market Facts & Figures by Country
3.4.1 North America Deferasirox Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Deferasirox Sales by Country (2019-2030)
3.4.3 North America Deferasirox Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Deferasirox Market Facts & Figures by Country
3.5.1 Europe Deferasirox Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Deferasirox Sales by Country (2019-2030)
3.5.3 Europe Deferasirox Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Deferasirox Market Facts & Figures by Country
3.6.1 Asia Pacific Deferasirox Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Deferasirox Sales by Country (2019-2030)
3.6.3 Asia Pacific Deferasirox Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Deferasirox Market Facts & Figures by Country
3.7.1 Latin America Deferasirox Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Deferasirox Sales by Country (2019-2030)
3.7.3 Latin America Deferasirox Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Deferasirox Market Facts & Figures by Country
3.8.1 Middle East and Africa Deferasirox Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Deferasirox Sales by Country (2019-2030)
3.8.3 Middle East and Africa Deferasirox Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Deferasirox Sales by Type (2019-2030)
4.1.1 Global Deferasirox Sales by Type (2019-2024)
4.1.2 Global Deferasirox Sales by Type (2025-2030)
4.1.3 Global Deferasirox Sales Market Share by Type (2019-2030)
4.2 Global Deferasirox Revenue by Type (2019-2030)
4.2.1 Global Deferasirox Revenue by Type (2019-2024)
4.2.2 Global Deferasirox Revenue by Type (2025-2030)
4.2.3 Global Deferasirox Revenue Market Share by Type (2019-2030)
4.3 Global Deferasirox Price by Type (2019-2030)
5 Segment by Application
5.1 Global Deferasirox Sales by Application (2019-2030)
5.1.1 Global Deferasirox Sales by Application (2019-2024)
5.1.2 Global Deferasirox Sales by Application (2025-2030)
5.1.3 Global Deferasirox Sales Market Share by Application (2019-2030)
5.2 Global Deferasirox Revenue by Application (2019-2030)
5.2.1 Global Deferasirox Revenue by Application (2019-2024)
5.2.2 Global Deferasirox Revenue by Application (2025-2030)
5.2.3 Global Deferasirox Revenue Market Share by Application (2019-2030)
5.3 Global Deferasirox Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Deferasirox Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Deferasirox Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Cipla
6.2.1 Cipla Corporation Information
6.2.2 Cipla Description and Business Overview
6.2.3 Cipla Deferasirox Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Cipla Deferasirox Product Portfolio
6.2.5 Cipla Recent Developments/Updates
6.3 Natco Pharma
6.3.1 Natco Pharma Corporation Information
6.3.2 Natco Pharma Description and Business Overview
6.3.3 Natco Pharma Deferasirox Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Natco Pharma Deferasirox Product Portfolio
6.3.5 Natco Pharma Recent Developments/Updates
6.4 Sun Pharma
6.4.1 Sun Pharma Corporation Information
6.4.2 Sun Pharma Description and Business Overview
6.4.3 Sun Pharma Deferasirox Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sun Pharma Deferasirox Product Portfolio
6.4.5 Sun Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Deferasirox Industry Chain Analysis
7.2 Deferasirox Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Deferasirox Production Mode & Process
7.4 Deferasirox Sales and Marketing
7.4.1 Deferasirox Sales Channels
7.4.2 Deferasirox Distributors
7.5 Deferasirox Customers
8 Deferasirox Market Dynamics
8.1 Deferasirox Industry Trends
8.2 Deferasirox Market Drivers
8.3 Deferasirox Market Challenges
8.4 Deferasirox Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
